Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DMAC 
DiaMedica Therapeutics Inc (DMAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: DMAC (1-star) is a SELL. SELL since 5 days. Profits (13.58%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 24.67% | Avg. Invested days 41 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 163.71M USD | Price to earnings Ratio - | 1Y Target Price 8.75 |
Price to earnings Ratio - | 1Y Target Price 8.75 | ||
Volume (30-day avg) 82156 | Beta 1.52 | 52 Weeks Range 2.14 - 6.82 | Updated Date 04/1/2025 |
52 Weeks Range 2.14 - 6.82 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.6 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.1725 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.18% | Return on Equity (TTM) -53.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 119901621 | Price to Sales(TTM) - |
Enterprise Value 119901621 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.96 | Shares Outstanding 42855700 | Shares Floating 24174878 |
Shares Outstanding 42855700 | Shares Floating 24174878 | ||
Percent Insiders 26.12 | Percent Institutions 34.19 |
Analyst Ratings
Rating 4.75 | Target Price 8 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
DiaMedica Therapeutics Inc
Company Overview
History and Background
DiaMedica Therapeutics Inc. was founded in 2010 and is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases. They are primarily focused on developing recombinant human tissue kallikrein-1 (rhKLK1) to improve clinical outcomes for patients with unmet medical needs.
Core Business Areas
- Neurological Disorders: Developing DM199, a recombinant human tissue kallikrein-1 (rhKLK1), for acute ischemic stroke.
- Kidney Diseases: Developing DM199 for chronic kidney disease (CKD) and other renal disorders.
Leadership and Structure
Rick Pauls is the President and CEO. The company has a board of directors overseeing its operations and strategic direction. The organizational structure includes clinical development, regulatory affairs, and business development functions.
Top Products and Market Share
Key Offerings
- DM199 (Acute Ischemic Stroke): DM199 is DiaMedica's lead product candidate for the treatment of acute ischemic stroke (AIS). It's a recombinant form of human tissue kallikrein-1 (KLK1), an enzyme that plays a key role in regulating blood flow and preventing blood clots. Market share data is currently unavailable as it is still in clinical trials. Competitors include companies developing thrombolytic agents (e.g., tPA) and other stroke therapies.
- DM199 (Chronic Kidney Disease): DM199 is also being developed for the treatment of chronic kidney disease (CKD). The company believes that DM199 can improve kidney function and reduce the risk of cardiovascular events in patients with CKD. Market share data is currently unavailable as it is still in clinical trials. Competitors include companies developing treatments for CKD progression and its complications.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with high regulatory hurdles and significant development costs. The market for stroke and kidney disease therapeutics is large and growing, driven by aging populations and increasing prevalence of these conditions.
Positioning
DiaMedica is positioned as a company developing a novel therapeutic approach for stroke and kidney disease. Its competitive advantage lies in the unique mechanism of action of DM199 and its potential to address unmet needs in these areas.
Total Addressable Market (TAM)
The TAM for stroke therapeutics is estimated to be several billion dollars annually. Similarly, the market for CKD therapeutics is substantial and projected to grow. DiaMedica is positioned to capture a share of these markets if DM199 is approved.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with DM199
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on single product candidate
- Clinical trial risks
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory setbacks
Competitors and Market Share
Key Competitors
- ALNY
- IONS
- VRTX
Competitive Landscape
DiaMedica faces competition from companies developing established therapies and novel approaches for stroke and kidney disease. Its competitive advantage lies in the unique mechanism of action of DM199, but it faces challenges due to its limited resources and dependence on a single product candidate.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and fundraising activities rather than revenue generation.
Future Projections: Future growth is contingent on the successful development and commercialization of DM199. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing clinical trials of DM199 in stroke and kidney disease and seeking partnerships to support development and commercialization.
Summary
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company with a novel drug candidate, DM199, targeting stroke and kidney disease. Its success hinges on the outcome of ongoing clinical trials. While DM199 has a unique mechanism of action and targets large markets, the company faces challenges related to funding, competition, and regulatory hurdles. Positive clinical trial results would significantly improve the company's prospects.
Similar Companies
- ALNY
- IONS
- VRTX
- REGN
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data and analysis are based on publicly available information and are subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DiaMedica Therapeutics Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2008-01-04 | President, CEO & Director Mr. Dietrich John Pauls MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.diamedica.com |
Full time employees 27 | Website https://www.diamedica.com | ||
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.